Nasal Flu Vaccine Is Approved for At-Home Use

Published On Sep 20, 2024, 2:46 PM

The FDA has granted AstraZeneca approval for the at-home use of its FluMist nasal spray vaccine, allowing individuals to administer it themselves after obtaining a prescription online. This new option is aimed at improving accessibility and convenience for people, particularly those averse to needles. The approval is seen as significant, especially for children who can be vaccinated by caregivers. FluMist will remain available through traditional healthcare providers as well.

Read full article

Stock Forecasts

AZNView AZN chart on TradingView

Positive

With the new at-home use approval for FluMist vaccine, AstraZeneca is likely to see an increase in demand, leading to potential revenue growth. This strategic shift could open up a new market segment that prefers at-home health solutions.

Related News

Nasal Flu Vaccine Is Approved for At-Home Use

Sep 20, 2024, 2:46 PM

The F.D.A. authorized AstraZeneca to prescribe the treatment online for at-home use after a study showed it was feasible.

AZN